News

Augmenix, Inc. Announces Aetna’s Positive Coverage Decision for the SpaceOAR® Hydrogel Procedure for Men with Prostate Cancer

BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Inc. is pleased to announce that Aetna, Inc, the third largest commercial health plan Read more...

Ovarian Cancer Doesn’t Begin in the Ovaries, Researchers Say

Ovarian cancer begins with lesions in the fallopian tubes, which if treated early could prevent the cancer from spreading, researchers say A growing body Read more...

Key Strategies for Implementing Proteomics-Based Tests Across Disease States

Xpresys® Lung and PreTRM® Tests Featured as Demonstrating Pathway to Successful Development and Clinical Implementation SEATTLE and SALT LAKE CITY, Read more...

Bill Gates Tells Healthcare’s Capitalists How To Save Five Million Kids

Bill Gates is about to address thousands of top executives, bankers and investors at the year's biggest healthcare industry gathering. His Read more...

Augmenix® Announces Medicare Reimbursement Rates for the new CPT Code 55874, which will be used to bill SpaceOAR® Hydrogel, Effective January 2018

First and only prostate cancer spacing device available for use in the U.S. clinically proven to preserve patient quality of life following radiation therapy BEDFORD, Read more...

Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy Of Spaceoar Hydrogel In Patients Undergoing Dose-Escalated Stereotactic Body Radiation Therapy For Prostate Cancer

Application of SpaceOAR hydrogel significantly reduces rectal injury in a high-dose SBRT treated patient population BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Read more...

Augmenix to Unveil New Clinical Data on its Innovative Absorbable Hydrogel Technology at the 59th Annual Meeting of the American Society for Radiation Oncology

BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that Read more...

Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year

Augmenix Maintains Spot in Top 10% of Metro-Boston Companies; Three-Year Growth over 2,000% Ranked Company Number 207 on Inc. Magazine’s Top 500 BEDFORD, Read more...

Page 1 of 29123...Last »

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184